The primary function of Posterisan is to provide supportive relief when symptoms interfere with routine activities related to anorectal conditions. The medicine is generally used for managing symptoms related to inflammatory or irritative states, such as those associated with hemorrhoids and dermatitis around the anus.

The medicine is commonly used to help with symptom clusters that may become intense or disruptive, including bleeding, pain, swelling, and itchiness. This makes the product relevant for easing the overall symptom burden linked to organ-specific functional stress. Conditions characterized by periods of heightened symptoms where the product may be applied include hemorrhoids, dermatitis around the anus, anal fissures, and surgical wounds in the anus.

The formulation is relevant for easing symptoms related to inflammatory or irritative states and is applied in addressing symptoms that create noticeable physiological strain, which may assist with maintaining functional stability. It helps maintain a sense of stability when symptoms are more noticeable, supporting general well-being during symptomatic phases.

“Posterisan is commonly used across conditions presenting with acute episodes, providing symptomatic relief that helps patients cope more steadily.”

---

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

1. Japanese regulatory authority Drug Information Sheet

Eligibility Map: Who can and cannot use Posterisan — official regulatory information

Contraindicated Populations

Use of Posterisan is contraindicated in individuals with known hypersensitivity (allergy) to any of the active substances (Standardized E. coli suspension, Lidocaine, or Hydrocortisone Acetate) or any of the inactive excipients. Additionally, the corticosteroid-containing variant (Posterisan corte) is contraindicated in the presence of tuberculous, luetic (syphilitic), or viral processes at the site of application.

Age-Related Eligibility

• Adults are the standard eligible population for use.
• Children and adolescents under 12 years are generally not recommended or not established as an eligible group for the Lidocaine variant (Posterisan akut). Use in children under 12 for the Hydrocortisone variant (Posterisan corte) requires strict medical supervision.

Physiological and Comorbidity Restrictions

• Pregnancy and Lactation: Use during these periods is generally only permitted if considered absolutely necessary by a physician due to limited safety data or the potential for systemic absorption of Lidocaine or Hydrocortisone.
• Severe Hepatic/Renal Impairment: Caution is advised when using the Lidocaine-containing variant due to the metabolism and excretion of the substance.
• Local Infection: The presence of a fungal infection requires simultaneous local treatment with an antifungal agent.

Eligibility Classifications

Regulatory documents classify non-eligibility into Contraindicated (absolute prohibition) or Restricted/Conditional Use (permitted only under medical necessity or caution), establishing the official boundary for safe population use.

Interactions with other medicines and products

Posterisan contains the corticosteroid component hydrocortisone, which is locally administered. Although systemic absorption is typically low, the possibility of drug interactions must be considered, particularly with prolonged use, large application areas, or damaged skin.

Interaction Scope

Interaction Class	Description
Systemic Corticosteroids	Concurrent use of Posterisan with other systemic corticosteroid medicines may increase the risk of systemic side effects, which are a class effect of corticosteroids.
Specific Interacting Medicines	No specific non-corticosteroid medicines are consistently or explicitly listed as interacting with the local hydrocortisone component of Posterisan.
Interaction Mechanism	The documented interaction basis relates to a cumulative pharmacologic effect, where co-administration of another medicine from the same corticosteroid class may increase overall systemic exposure and the potential for dose-dependent adverse effects.

Important Considerations

Patients using any other medication, whether prescription or over-the-counter, including supplements or herbal products, should inform their healthcare provider. The primary interaction-related restriction involves the elevated potential for systemic side effects when this product is combined with other corticosteroids.

Local Immunomodulation and Tissue Regeneration

The core mechanism, driven by the Standardized Suspension of Inactivated E. coli, involves modulating local immune cells and epithelial colonocytes via pattern recognition receptors. This interaction stimulates the production of defensins and growth factors, which modulates local antimicrobial activity and cellular pathways associated with epithelial repair and structural integrity of the mucosa.

---

Rapid Sensory Blockade and Nerve Stabilization

In variants containing Lidocaine, the primary action is the reversible blockade of peripheral voltage-gated sodium ( Na^+) channels on sensory neurons. By preventing the influx of Na^+ ions, the mechanism stabilizes the neuronal membrane, suppressing the generation of nerve impulses and the subsequent transmission of somatosensory signals.

---

Gene-Level Anti-Inflammatory Modulation

Variants containing Hydrocortisone exert their effect by acting as an agonist for cytoplasmic Glucocorticoid Receptors (GR). This initiates a gene transcription modulation cascade that upregulates anti-inflammatory proteins (like Lipocortin-1) and downregulates pro-inflammatory mediators, leading to the physiological consequence of reduced capillary permeability and limited localized fluid exudation.

Posterisan preparations are administered via targeted route and dosage form selection, which dictates application either topically to the perianal skin or rectally through insertion into the anal canal. The product is available as a rectal ointment and as suppositories, with the choice often depending on the primary application site.

Dosing and Frequency

Official instructions establish a regulated dosing frequency typically set at one to three times daily, regardless of the specific formulation. Suppositories and the basic ointment formulation are often recommended for use once or twice a day, frequently scheduled for morning and evening.

Application should preferably occur after defecation to maximize contact time with the affected tissue. The prescribed amount of ointment is generally an “appropriate amount,” though the Lidocaine-containing variant (akut) has a specific restriction: the applied dose should not exceed 2.5 g per application.

Administration Technique and Constraints

For internal ointment application, a specific administration technique is required, involving the use of an enclosed applicator or nozzle. Instructions advise lubricating the nozzle by squeezing out a small amount of ointment before insertion to ease application.

Crucially, time-limited use applies to the Lidocaine-containing formulation (akut), which is officially restricted to a maximum duration of three days without further medical evaluation. Additionally, this specialized variant is prohibited for use in children and adolescents under 18 years in some jurisdictions.

Research Evidence / Overview of Studies for Posterisan

This section provides an overview of the research that has explored the active ingredients in Posterisan, focusing on the types of studies conducted, the specific outcomes measured, and the overall completeness of the evidence base, without offering clinical recommendations.

---

Evidence Structure for Hemorrhoidal Disease

The clinical evaluation of the active components in Posterisan, particularly the Standardized Suspension of Inactivated E. coli, has been documented in peer-reviewed scientific literature exploring outcomes related to symptomatic hemorrhoidal conditions. Research in this area has utilized several structured approaches, including Randomized Controlled Trials (RCTs) and meta-analyses that synthesized data from multiple clinical studies. These designs involved a comparison of the product against a vehicle or other active agents.

In these trials, research examined changes in several patient-reported outcomes describing perceived discomfort, such as pain, swelling, itching, and bleeding. Researchers also monitored physical measures related to outcomes describing tissue repair and documented changes in the patient's overall condition. Studies was observed in primarily during periods of increased symptom activity and focused on short-term symptom changes in adult populations.

---

Evidence Structure for Perianal Eczema and Dermatitis

Research has explored the application of the product's components in research exploring outcomes related to inflammatory anal conditions such as perianal eczema and dermatitis. The evidence for this indication includes controlled comparative studies and systematic reviews which focus on how outcomes linked to localized inflammation and irritation were measured. These studies examined outcomes linked to inflammatory or irritative states, such as changes in burning, redness, and itching, usually recorded through standardized summed symptom scores.

---

What is Still Uncertain and Research Gaps

The research base, while covering multiple studies, still presents specific limitations that contribute to overall uncertainty regarding the evidence. Follow-up durations were limited in core trials, meaning that understanding how patient-reported outcomes evolve months after the study period and whether long-term findings are available are not well characterized. Additionally, data for certain groups remain insufficient, including evidence for special populations or the long-term usage profile.

Key Studies & References

1. Drug Information Sheet (Used for symptom clusters and indications)

Common questions about Posterisan (FAQ)

---

Q: What is the difference between Posterisan and Posterisan akut or corte?

According to official product information, Standard Posterisan contains only the Standardized Suspension of Inactivated E. coli.

The specialized variants are differentiated by their added active ingredients: Posterisan akut also contains the local anesthetic Lidocaine, and Posterisan corte also contains the corticosteroid Hydrocortisone.

---

Q: How long is it safe to use Posterisan for?

The maximum duration of use is variant-specific, based on the specialized components, as cited in regulatory documents.

Official information states that the Lidocaine-containing variant (akut) is generally restricted to a maximum of three consecutive days without further medical evaluation. The Hydrocortisone-containing variant (corte) is typically limited to a maximum of 10 consecutive days.

---

Q: Can I use Posterisan if I am pregnant or breastfeeding?

Official information indicates that use during pregnancy or breastfeeding is generally not recommended unless a physician determines that it is absolutely necessary.

This caution is advised due to limited human safety data and the possibility of systemic absorption—meaning the active ingredients like Lidocaine or Hydrocortisone could potentially enter the bloodstream—of the specialized components.

---

Q: What should I do if I miss a dose of the ointment or suppositories?

If a regular dose is missed, regulatory patient information commonly states that a dose may be applied as soon as it is remembered.

However, if it is almost time for the next scheduled application, the patient information typically states to skip the missed dose and continue with the regular schedule. Regulatory guidance advises against using a double dose to compensate for the one that was missed.

Posterisan ointment should be stored in a cool, dry area at room temperature, typically between 1 C and 30 C, unless otherwise specified on the packaging. Keep the medication in its original, tightly sealed container, away from excessive moisture, heat, and direct sunlight. It is essential to ensure the product is stored out of the sight and reach of children.

Disposal

To dispose of unused or expired Posterisan, do not flush the medication down the toilet or pour it into a drain unless specifically instructed to do so by an authorized health authority. The most appropriate methods for disposal are usually through a local medicine take-back program or by consulting your pharmacist for guidance on safe and environmentally responsible disposal options. This protects the water supply and prevents accidental exposure.